William S. Velasquez

Author

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Velasquez, W., Velásquez W, Velásquez, William, W S Velasquez, W Velasquez, W Velásquez, W. S. Velasquez, W. S. Velásquez, W. Velasquez, W.E. VELASQUEZ

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Lymphoma Research Foundation Anderson Hospital Texas Medical Center The University of Texas System

About

William S. Velasquez is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	28	2.4K
2	Health Sciences	12	13	1.2K
3	Public Health	1	1	238
4	Cellular Therapies	1	1	69
5	Gastroenterology	1	1	110

William S. Velasquez

Publications

4.2K

Citations

H-Index

Page 1

	Year	Citations
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia MJ Keating, H. Kantarjian, Moshe Talpaz, Blood	1989	455
ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. William S. Velasquez, Peter McLaughlin, Fredrick B. Hagemeister, Journal of Clinical Oncology	1994	427
Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab Thomas A. Davis, Christine A. White, A.J. Grillo-López, Journal of Clinical Oncology ImmunologyImmunotherapyHematological MalignancyOncologyHematology	1999	289
Fludarabine: a new agent with major activity against chronic lymphocytic leukemia MJ Keating, Hagop M. Kantarjian, Moshe Talpaz, Blood	1989	262
Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. Miguel F Cunha, Marvin L. Meistrich, Lillian M. Fuller, Journal of Clinical Oncology SpermatogenesisFertilityReproductive HealthChemotherapy CyclesGynecology	1984	238
Results of MIME salvage regimen for recurrent or refractory lymphoma. Fernando Cabanillas, Fredrick B. Hagemeister, Peter McLaughlin, Journal of Clinical Oncology Lymphoid NeoplasiaSurgical OncologyMedicineMime RegimenImmunology	1987	228
Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. Sundar Jagannath, Jamés O. Armitage, K. A. Dicke, Journal of Clinical Oncology Prognostic FactorsTransplantation MedicineImmunologyCell Replacement TherapyPharmacotherapy	1989	210
A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. F Swan, William S. Velasquez, S. C. Tucker, Journal of Clinical Oncology Ann ArborLymphoid NeoplasiaMedicineLactate DehydrogenaseSurgical Pathology	1989	159
MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. Fredrick B. Hagemeister, Nizar M. Tannir, Peter McLaughlin, Journal of Clinical Oncology ImmunologyPathologyRecurrent HodgkinPharmacotherapyImmunotherapy	1987	131
Stages IE and IIE non-Hodgkin's lymphomas of the stomach: Comparison of treatment modalities Moshe Maor, Brian N. Maddux, Barbara M. Osborne, Cancer Lymphoid NeoplasiaSurgical OncologyGastrointestinal OncologyMedicineSurgical Pathology	1984	110

Page 1